Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus—A prospective randomized trial

Sugimachi, Keizō; Kitamura, Kenichiro; Baba, Kanji; Inamori, Masahiko; Morita, Masaru; Matsuda, Hiroyuki; Kuwano, Hiroyuki

doi:10.3109/02656739209021783

Cited by 68 publications

(38 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In some randomized trials, it has been verified that preoperative chemoradiotherapy improves the survival rate of esophageal cancer patients. Although comparatively few centers perform preoperative chemoradiotherapy because of the high-quality surgical treatment available in Japan, one randomized trial report has shown that hyperthermochemoradiotherapy was effective in the local control of esophageal cancer [53]. There are five meta-analyses based on five to seven randomized trials comparing preoperative chemoradiotherapy followed by surgery with surgery alone.…”

Section: Combined-modality Treatmentmentioning

confidence: 99%

Surgical Treatment for Esophageal Cancer

Kato

Fukuchi²,

Miyazaki³

et al. 2007

Dig Surg

View full text Add to dashboard Cite

Esophageal cancer is one of the most difficult malignancies to cure. The prognosis remains unsatisfactory despite significant advances in surgical techniques and perioperative management. The optimal treatment strategy for localized esophageal cancer has not yet been established. Surgical resection remains the mainstay of treatment for esophageal cancer, and curative resection is the most important surgery. Extended esophagectomy with three-field lymphadenectomy provides the highest quality of tumor clearance and prolongation of patient survival. There has been intense effort in developing novel strategies to treat patients with resectable esophageal cancer. Various combined-modality approaches have been attempted to improve treatment outcomes. Definitive chemoradiotherapy has an impact on long-term survival in patients with resectable esophageal cancer. Accordingly, there are three main combined-modality approaches: esophagectomy with adjuvant chemotherapy or chemoradiotherapy; primary definitive chemoradiotherapy with or without salvage esophagectomy, and preoperative chemoradiotherapy followed by planned esophagectomy. Recently, owing to the remarkable advances in optical technology, minimally invasive esophagectomy using endoscopic instruments has been introduced into esophageal cancer surgery. This article reviews recent changes in the treatment of esophageal cancer surgery, and considers the role of esophagectomy.

show abstract

Section: Combined-modality Treatmentmentioning

confidence: 99%

Surgical Treatment for Esophageal Cancer

Kato

Fukuchi²,

Miyazaki³

et al. 2007

Dig Surg

View full text Add to dashboard Cite

show abstract

“…Objective tumor regression, histopathological effectiveness of the preoperative regimen and improvement of dysphagia were substantially better in the treatment arm combined with hyperthermia [43]. However, the number of pathological CR with no viable cancer cells in the resected specimens were significantly increased when preoperative radiotherapy was also used in addition to thermochemotherapy ('triple modality') as has been shown in previous trials [44,45].…”

Section: Cancer Of the Esophagusmentioning

confidence: 73%

Hyperthermia Combined with Chemotherapy – Biological Rationale, Clinical Application, and Treatment Results

Issels¹

1999

Oncol Res Treat

View full text Add to dashboard Cite

There is substantial evidence from preclinical data that the antitumor cytotoxicity of selected chemotherapeutic agents either alone or combined with radiation can be enhanced by appropriate heat exposure (40–44 °C) of cells or tumor tissues. Based upon these results the integration of hyperthermia as an additional treatment modality, given simultaneously with systemic chemotherapy or in combination with radiochemotherapy, is currently tested at the clinic. Regional hyperthermia combined with chemotherapy or radiochemotherapy showed impressive results (phase II studies) at clinical relevant temperatures in locally advanced tumors of different entities in terms of objective response rate, local tumor control and relapse-free survival. Clinical protocols of well-designed phase III trials on combined treatment modalities integrating hyperthermia are rather limited but for some tumors confirm its clinical benefit. In general, the clinical approach to use hyperthermia has gained much more interest within in the field of medical oncology. One of the major reason is the substantial technical improvements made with the available commercial equipment for local or regional heating, especially in case of deep-seated lesions or systemic heating. Further testing of the potential of hyperthermia combined with chemotherapy or radiochemotherapy in prospective randomized trials are warranted. At this time, hyperthermia as an adjunct to conventional treatment strategies is recommended in the setting of clinical protocols. The results of prospective trials should answer the question for which types of local advanced or metastatic tumors hyperthermia becomes standard as part of a multimodal treatment strategy.

show abstract

“…The heat sensitivity of the tumor tissue was higher than that of the adjacent normal tissue, in each case [18]. Patients with carcinoma of the esophagus or of the rec tum are known to benefit from hyperthermia treatment [ 19,20]. A major problem is the application of heat to deeply located lesions.…”

Section: Discussionmentioning

confidence: 99%

Use of the Succinate Dehydrogenase Inhibition Test in Assessing the Heat Sensitivity of Tumor Cells

Kohnoe

Maehara²,

Takahashi

et al. 1993

Oncology

View full text Add to dashboard Cite

The in vitro succinate dehydrogenase (SD) inhibition (SDI) test was used to determine the heat sensitivity of tumor cell lines and human tumor cells. The tumor cells were exposed to heat in vitro and the decrease in SD activity was assayed using a colorimetric assay, the SDI test. With respect to survival curves of HeLa cells, the SDI test correlated well with the clonogenic assay and the dye exclusion assay. Decrease in the SD activity of HeLa cells after the heat treatment (41–44 °C, 10 min to 5 h) depended on both the temperature and the duration of heat exposure. S- and G₂/M-phase-rich HeLa cells were more sensitive to heat than were the G₁-phase-rich cells. The SDI test exhibited a wide variation in the heat sensitivity among four cell lines (HeLa, B-16, V-79, and a human GT-1 squamous cell carcinoma). Variation in heat sensitivity was also detected among individual tumor tissues obtained from clinical specimens of gastric, esophageal, and colorectal cancers. Gastric cancer tissues were more sensitive to heat than were esophageal and colorectal tissues. We recommended that if the SDI test is used to assess the heat sensitivity of clinical tumor tissues in vitro, appropriate therapy for individual patients can be designed.

show abstract

Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus—A prospective randomized trial

Cited by 68 publications

References 12 publications

Surgical Treatment for Esophageal Cancer

Surgical Treatment for Esophageal Cancer

Hyperthermia Combined with Chemotherapy – Biological Rationale, Clinical Application, and Treatment Results

Use of the Succinate Dehydrogenase Inhibition Test in Assessing the Heat Sensitivity of Tumor Cells

Contact Info

Product

Resources

About